Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) announced dosing of the first patients in the Phase 2 portion of its Phase 1/2 trial of ABCL635, a potential first-in-class non-hormonal therapy for moderate-to-severe vasomotor symptoms (VMS) of menopause. The Phase 2 is a multicenter, randomized, double‑blind, placebo‑controlled Proof-of-Concept study in 80 postmenopausal women. The move to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from Phase 1 healthy volunteers and evidence of high target engagement. With Phase 2 enrollment underway, the company anticipates top-line results for both phases in Q3 2026.
AbCellera (Nasdaq: ABCL) announced a global settlement and patent license agreement with Bruker on December 18, 2025. As part of the deal, Bruker will pay $36 million up front and will make future royalty payments on sales of Bruker's Beacon® Optofluidic platform worldwide through the life of the licensed patents. The agreement resolves the companies' global patent litigation and grants Bruker a license to the covered patents.
AbCellera (Nasdaq: ABCL) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live audio webcast will be available via a link posted on AbCellera's Investor Relations website, with a replay accessible after the presentation.
AbCellera (Nasdaq: ABCL) appointed Stephen Quake, D.Phil., to its Board of Directors as an independent director effective November 10, 2025.
Dr. Quake is a prominent scientist and entrepreneur with >300 publications, an h-index of 181, 80+ patents, leadership roles at Stanford and Caltech, and service as founding co-president and later head of science for the Chan Zuckerberg Biohub Network (launch budget ~$600 million). Concurrently, Andrew W. Lo, Ph.D., resigned after joining the board in December 2021 and serving on Audit and Nominating and Corporate Governance Committees.
AbCellera (Nasdaq: ABCL) reported Q3 2025 results for the period ended September 30, 2025. Key operational highlights include starting activities at a new clinical manufacturing facility, substantially completing platform investments, and appointing Sarah Noonberg, M.D., Ph.D. as chief medical officer.
Financials: Revenue $9.0M versus $6.5M a year earlier; net loss $57.1M ($(0.19) per share) versus $51.1M in Q3 2024. R&D spend rose to $55.0M, including $15.0M on two internal programs. Liquidity totaled approximately $680M including $523M cash and $159M government funding.
Operational metrics: 103 partner-initiated program starts with downstreams and 18 molecules in the clinic.
AbCellera (Nasdaq: ABCL) will participate in multiple investor conferences in November and December 2025.
Scheduled events: Truist Securities BioPharma Symposium on November 6, 2025; Stifel Healthcare Conference on November 11–13, 2025; Jefferies Global Healthcare Conference on November 18–20, 2025; and Piper Sandler 37th Annual Healthcare Conference on December 2–4, 2025. Visit the company Investor Relations website for additional information and access details.
AbCellera (NASDAQ:ABCL) has scheduled its third quarter 2025 financial results announcement for Thursday, November 6, 2025. The company will host an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. Investors can access the live audio webcast through AbCellera's Investor Relations website, where a replay will also be available after the call.
AbCellera (Nasdaq: ABCL) has appointed Dr. Sarah Noonberg as its first Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist with over 20 years of industry experience, brings extensive expertise in clinical development across various therapeutic areas including oncology, neuroscience, rare diseases, and gene therapy.
Previously serving as CMO at Metagenomi, where she helped secure a $100M IPO, Dr. Noonberg will now focus on advancing AbCellera's pipeline of antibody-based therapeutics. Her impressive background includes leadership roles at Maze Therapeutics, Nohla Therapeutics, Prothena Biosciences, and BioMarin, along with significant contributions to the development of XTANDI™ for prostate cancer at Medivation.
AbCellera (Nasdaq: ABCL) has initiated a Phase 1 clinical trial for ABCL575, dosing the first participants in a study targeting moderate-to-severe atopic dermatitis. The investigational antibody therapy is engineered with unique characteristics, including Fc-silencing and half-life extension, allowing for a dosing interval of once every six months - a significant improvement over current clinical-stage alternatives.
The trial (NCT07108894) is designed as a randomized, placebo-controlled, double-blind study evaluating safety and tolerability in healthy participants receiving subcutaneous doses. The company expects to report data from this study in mid 2026. The therapy, which targets OX40 ligand, shows potential for treating other inflammatory and autoimmune conditions beyond atopic dermatitis.
AbCellera (Nasdaq: ABCL) announced its participation in two upcoming investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference from September 3-5, and the Morgan Stanley Annual Global Healthcare Conference from September 8-10. Additional information can be found on AbCellera's Investor Relations website.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
